# US 7,611,720 B2 · Tuberculosis vaccines including recombinant BCG strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,611,720 B2 - Document ID: US7611720B2 - Status: Granted - Kind: B2 - Application number: 10/511,718 - Filed: 2003-04-16 - Published: 2007-11-15 - Granted: 2009-11-03 - Earliest claimed: 2002-04-16 - Assignees: Jun Liu - Inventors: Jun Liu; Jeffrey Chen; David Alexander - Web page: https://patentgrep.com/patent/US7611720B2 ## CPC - C12N 9/0016: {with NAD or NADP as acceptor (1.4.1)} - A61P 31/04: Antibacterial agents - A61P 31/06: for tuberculosis - A61P 35/00: Antineoplastic agents - C12N 9/88: Lyases (4.) - C12N 9/93: {Ligases (6)} - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention relates to a live recombinant Mycobacterium bovis-BCG strain comprising a nucleic acid capable of expression, the nucleic acid encoding at least one protein or polypeptide that exhibits alanine dehydrogenase activity, glutamine synthetase activity, or serine dehydratase activity. ## Claims ### Claim 1 A live recombinant Mycobacterium bovis-BCG strain comprising a heterologous nucleic acid capable of expression, the heterologous nucleic acid encoding at least one protein or polypeptide that exhibits alanine dehydrogenase activity, glutamine synthetase activity, or L-serine dehydratase activity. ### Claim 2 (depends on 1) The live recombinant Mycobacterium bovis-BCG strain of claim 1, wherein the at least one protein or polypeptide is selected from the group consisting of alanine dehydrogenase [SEQ ID NO:1; SEQ ID NO:2], glutamine synthetase [SEQ ID NO:7 to SEQ ID NO:14] and L-serine dehydratase [SEQ ID NO:5; SEQ ID NO:6]. ### Claim 3 (depends on 1) The live recombinant Mycobacterium bovis-BCG strain of claim 1, wherein the nucleic acid comprises all or part of at least one nucleic acid molecule selected from the group consisting of [SEQ ID NO:1], [SEQ ID NO:5], [SEQ ID NO:7], [SEQ ID NO:9], [SEQ ID NO:11], and [SEQ ID NO:13]. ### Claim 4 (depends on 1) The live recombinant Mycobacterium bovis-BCG strain of claim 1, wherein the nucleic acid comprises a sequence having at least 60% sequence identity to at least one nucleic acid molecule selected from the group consisting of [SEQ ID NO:1], [SEQ ID NO:5], [SEQ ID NO:7], [SEQ ID NO:9], [SEQ ID NO:11] and [SEQ ID NO:13]. ### Claim 5 (depends on 3) The live recombinant Mycobacterium bovis-BCG strain of claim 3, wherein the nucleic acid molecule has undergone modification. ### Claim 6 (depends on 1) The live recombinant Mycobacterium bovis-BCG strain of claim 1, wherein the Mycobacterium bovis-BCG strain is selected from the group consisting of Mycobacterium bovis-BCG-Russia, Mycobacterium bovis-BCG-Moreau, Mycobacterium bovis-BCG-Japan, Mycobacterium bovis-BCG-Sweden, Mycobacterium bovis-BCG-Birkhaug, Mycobacterium bovis-BCG-Prague, Mycobacterium bovis-BCG-Glaxo, Mycobacterium bovis-BCG-Den mark, Mycobacterium bovis-BCG-Tice, Mycobacterium bovis-BCG- Frappier, Mycobacterium bovis-BCG-Connaught, Mycobacterium bovis-BCG-Phipps, and Mycobacterium bovis-BCG-Pasteur. ### Claim 7 (depends on 1) A pharmaceutical composition comprising the live recombinant Mycobacterium bovis-BCG strain of claim 1. ### Claim 8 (depends on 1) A vaccine or immunogenic composition for treatment or prophylaxis of a mammal against challenge by Mycobacterium tuberculosis or Mycobacterium bovis comprising the live recombinant Mycobacterium bovis-BCG strain of claim 1. ### Claim 9 (depends on 8) The vaccine or immunogenic composition of claim 8, further comprising a pharmaceutically acceptable carrier. ### Claim 10 (depends on 8) The vaccine or immunogenic composition of claim 8, further comprising an adjuvant. ### Claim 11 (depends on 8) The vaccine or immunogenic composition of claim 8, further comprising immunogenic materials from one or more other pathogens. ### Claim 12 (depends on 1) A method for treatment or prophylaxis of a mammal against challenge by Mycobacterium tuberculosis or Mycobacterium bovis comprising administering to the mammal the live recombinant Mycobacterium bovis-BCG strain of claim 1. ### Claim 13 (depends on 12) The method of claim 12, wherein the mammal is a cow. ### Claim 14 (depends on 12) The method of claim 12, wherein the mammal is a human. ### Claim 15 (depends on 12) The method of claim 12, wherein the vaccine or immunogenic composition is administered in the presence of an adjuvant. ### Claim 16 (depends on 1) A method for treatment or prophylaxis of a mammal against cancer comprising administering to the mammal the live recombinant Mycobacterium bovis-BCG strain of claim 1. ### Claim 17 (depends on 16) The method of claim 16, wherein the vaccine or immunogenic composition is administered in the presence of an adjuvant. ### Claim 18 (depends on 16) The method of claim 16, wherein the cancer is bladder cancer. ### Claim 19 (depends on 1) A test kit comprising the live recombinant Mycobacterium bovis-BCG strain of claim 1. ### Claim 20 A medium composition for inhibiting the growth of Mycobacterium bovis-BCG comprising alanine or serine as the only nitrogen source for growth. ### Claim 21 (depends on 20) The medium composition of claim 20, further comprising: (a) a carbon source; (b) iron; (c) magnesium; and (d) SO4. ### Claim 22 (depends on 21) A medium composition of claim 21, wherein the carbon source is selected from the group consisting of glycerol, dextrose, citrate and glucose. ### Claim 23 A method of culturing Mycobacterium bovis-BCG comprising: (a) obtaining a sample of Mycobacterium bovis-BCG; and (b) culturing the sample in a medium comprising histidine. ### Claim 24 (depends on 4) The live recombinant Mycobacterium bovis-BCG strain of claim 4, wherein the nucleic acid molecule has undergone modification.